Predictive Performance of Neutrophil Gelatinase Associated Lipocalin, Liver Type Fatty Acid Binding Protein, and Cystatin C for Acute Kidney Injury and Mortality in Severely Ill Patients.

"CONFLICTS OF INTEREST: Prof. Alexandre Mebazaa reports personal fees from Novartis, Orion, Roche, Servier, Sanofi, Otsuka, Philips; grants and personal fees from Adrenomed and Abbott; and grants from 4TEEN4. He also owns fewer than 3,000 euros shares of S-Form Pharma Company. Dr. Naoki Sato reports honoraria and consulting fees from Otsuka, Novartis, BMS, Bayer, Terumo, Boehringer-Ingelheim, Daiichi-Sankyo, Ono, AstraZeneca, Taisho, and Kowa. Dr. Benjamin Deniau was invited to a meeting in Henningsdorf, Germany by 4TEEN4 Pharmaceuticals GmbH. The other authors declare no potential conflicts of interest with respect to the research authorship and/or publication of this article."

"RESEARCH FUNDING The FROG-ICU study was funded by the Programme Hospitalier de la Recherche Clinique (AON 10-216) and by a research grant from the Société Française d’Anesthésie-Réanimation. Abbot provided unrestricted free kits to Assistance Publique-Hôpitaux de Paris to conduct biomarker analyses."

"This study was an ancillary study of the FROG-ICU cohort study that assessed the prevalence of all-cause mortality in the year following ICU discharge in 20 French and Belgian ICUs between August 2011 and June 2013 []. Mechanical ventilation and/or use of vasopressors and/or inotropes for ≥24 hrs were criteria for inclusion []. This cohort study was conducted in France and Belgium in accordance with Good Clinical Practice and the Declaration of Helsinki 2002, validated by the relevant ethics committees (Comité de Protection des Personnes - Ile de France IV, institutional review board [IRB] No. 00003835; Commission d’Éthique Biomédicale Hospitalo-Facultaire de l’Hôpital de Louvain, IRB No. B403201213352), and registered on ClinicalTrials.gov (NCT01367093)."